Contineum Therapeutics Inc (CTNM) — Titan Protect Analysis

CTNM

Contineum Therapeutics Inc

Healthcare · ·

$11.49

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$469M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-6.91

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-26.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$22.00

+91% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 6 analysts covering this stock

About Contineum Therapeutics Inc

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic

https://www.contineum-tx.com

Country: United States Employees: 51 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.257

Positive but modest risk-adjusted returns

Kelly Fraction

0.0074

Marginal edge — very small allocation suggested

Calmar Ratio

-0.148

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-12.5%

Historical annualised return based on price data

Max Drawdown

-84.4%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

197

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.89

Less volatile than the market — more defensive

52W High

$16.33

30% below the year high

52W Low

$3.57

222% above the year low

Avg Volume

271,011

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.94

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

2.78

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-39,011,124

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-58,444,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$28.00

Target Median

$22.00

Target Low

$16.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go